# GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome

> **NCT01268761** · PHASE3 · COMPLETED · sponsor: **Instituto Valenciano de Infertilidad, IVI VALENCIA** · enrollment: 100 (actual)

## Conditions studied

- Ovarian Hyperstimulation Syndrome
- Effects of Gonadotropin
- Oocyte Maturation

## Interventions

- **DRUG:** GnRH antagonist (Cetrorelix)
- **DRUG:** Placebo (saline solution)

## Key facts

- **NCT ID:** NCT01268761
- **Lead sponsor:** Instituto Valenciano de Infertilidad, IVI VALENCIA
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2013-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01268761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01268761, "GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01268761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*